Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaHagop Kantarjian, Brian Druker|New England Journal of Medicine|2002Cited by 2k
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor FailureTimothy P. Hughes, Dong‐Wook Kim, Michael J. Mauro et al.|New England Journal of Medicine|2019Cited by 464
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive LeukemiaMatthew S. Zabriskie, Thomas O’Hare, Richard D. Press et al.|Cancer Cell|2014Cited by 366
An expanded universe of cancer targetsWilliam C. Hahn, Jitong Cai, Joel S. Bader et al.|Cell|2021Cited by 221
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CMLThomas O’Hare, Brian Druker|Blood|2004Cited by 198